Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.
Saved in:
| Title: | Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma. |
|---|---|
| Authors: | Shitara K; National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: kshitara@east.ncc.go.jp., Bang YJ; Seoul National University College of Medicine, Seoul, Republic of Korea., Wyrwicz LS; Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland., Rha SY; Yonsei University College of Medicine, Seoul, Republic of Korea., Oshima T; Kanagawa Cancer Center, Yokohama, Japan., Pietrantonio F; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Park YK; Chonnam National University Medical School, Hwasun, Republic of Korea., Lonardi S; Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Yañez P; Universidad de La Frontera, James Lind Cancer Research Center, Temuco, Chile., Yen CJ; National Cheng Kung University, Tainan, Taiwan., Metges JP; CHU-Brest-Institut de Cancerologie et d'Hematologie ARPEGO Network, Brest, France., Garrido M; Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Santiago, Chile., Moehler M; Johannes-Gutenberg University Clinic, Mainz, Germany., Pelles-Avraham S; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Yong WP; National University Cancer Institute Singapore (NCIS), Singapore., Spallanzani A; University Hospital of Modena, Modena, Italy., Jensen E; Merck & Co., Inc., Rahway, USA., Krishnan R; Merck & Co., Inc., Rahway, USA., Shih CS; Merck & Co., Inc., Rahway, USA., Al-Batran SE; Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany. |
| Source: | ESMO open [ESMO Open] 2026 Mar; Vol. 11 (3), pp. 106090. Date of Electronic Publication: 2026 Feb 26. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
